Cargando…

Lafora Disease: A Ubiquitination-Related Pathology

Lafora disease (LD, OMIM254780) is a rare and fatal form of progressive myoclonus epilepsy (PME). Among PMEs, LD is unique because of the rapid neurological deterioration of the patients and the appearance in brain and peripheral tissues of insoluble glycogen-like (polyglucosan) inclusions, named La...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Gimeno, Maria Adelaida, Knecht, Erwin, Sanz, Pascual
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116066/ https://www.ncbi.nlm.nih.gov/pubmed/30050012 http://dx.doi.org/10.3390/cells7080087

Ejemplares similares

Deciphering the Polyglucosan Accumulation Present in Lafora Disease Using an Astrocytic Cellular Model
por: Moreno-Estellés, Mireia, et al.
Publicado: (2023)

The Laforin–Malin Complex, Involved in Lafora Disease, Promotes the Incorporation of K63-linked Ubiquitin Chains into AMP-activated Protein Kinase β Subunits
por: Moreno, Daniel, et al.
Publicado: (2010)

An empirical pipeline for personalized diagnosis of Lafora disease mutations
por: Brewer, M. Kathryn, et al.
Publicado: (2021)

Laforin, the most common protein mutated in Lafora disease, regulates autophagy
por: Aguado, Carmen, et al.
Publicado: (2010)

Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level
por: Romá-Mateo, Carlos, et al.
Publicado: (2011)

Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease
por: Sanz, Pascual, et al.
Publicado: (2021)

A PTG Variant Contributes to a Milder Phenotype in Lafora Disease
por: Guerrero, Rosa, et al.
Publicado: (2011)

Reactive Glia Inflammatory Signaling Pathways and Epilepsy
por: Sanz, Pascual, et al.
Publicado: (2020)

Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model
por: Mollá, Belén, et al.
Publicado: (2022)

Ketogenic diet reduces Lafora bodies in murine Lafora disease
por: Israelian, Lori, et al.
Publicado: (2020)

Everolimus does not prevent Lafora body formation in murine Lafora disease
por: Mishra, Navin, et al.
Publicado: (2017)

PTG Depletion Removes Lafora Bodies and Rescues the Fatal Epilepsy of Lafora Disease
por: Turnbull, Julie, et al.
Publicado: (2011)

Glial Contributions to Lafora Disease: A Systematic Review
por: Della Vecchia, Stefania, et al.
Publicado: (2022)

Identification of proteins potentially involved in the formation of Lafora bodies, a hallmark of Lafora disease
por: Schokraie, Elham, et al.
Publicado: (2013)

Unusual Course of Lafora Disease
por: Zutt, Rodi, et al.
Publicado: (2016)

Lafora disease: a case report
por: Zeka, Naim, et al.
Publicado: (2022)

TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases
por: Kumarasinghe, Lorena, et al.
Publicado: (2021)

Increased Endoplasmic Reticulum Stress and Decreased Proteasomal Function in Lafora Disease Models Lacking the Phosphatase Laforin
por: Vernia, Santiago, et al.
Publicado: (2009)

Age-Related microRNA Overexpression in Lafora Disease Male Mice Provides Links between Neuroinflammation and Oxidative Stress
por: Romá-Mateo, Carlos, et al.
Publicado: (2023)

Lafora Disease Masquerading as Hepatic Dysfunction
por: Inayat, Faisal, et al.
Publicado: (2018)

Lafora disease in miniature Wirehaired Dachshunds
por: Swain, Lindsay, et al.
Publicado: (2017)

Retinal alterations in patients with Lafora disease
por: Heitkotter, Heather, et al.
Publicado: (2021)

Trehalose Treatment in Zebrafish Model of Lafora Disease
por: Della Vecchia, Stefania, et al.
Publicado: (2022)

Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan
por: Sullivan, Mitchell A., et al.
Publicado: (2017)

Lafora Disease: Report of a Rare Entity
por: Al Mufargi, Younis, et al.
Publicado: (2020)

Structure-Function Analysis of PPP1R3D, a Protein Phosphatase 1 Targeting Subunit, Reveals a Binding Motif for 14-3-3 Proteins which Regulates its Glycogenic Properties
por: Rubio-Villena, Carla, et al.
Publicado: (2015)

Vagus nerve stimulation in Lafora body disease()
por: Hajnsek, Sanja, et al.
Publicado: (2013)

Treatment with metformin in twelve patients with Lafora disease
por: Bisulli, Francesca, et al.
Publicado: (2019)

Role of Astrocytes in the Pathophysiology of Lafora Disease and Other Glycogen Storage Disorders
por: Duran, Jordi
Publicado: (2023)

Genetics of Lafora progressive myoclonic epilepsy: current perspectives
por: Kecmanović, Miljana, et al.
Publicado: (2016)

Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism
por: Couarch, Philippe, et al.
Publicado: (2011)

Retinal Phenotyping of a Murine Model of Lafora Disease
por: Vincent, Ajoy, et al.
Publicado: (2023)

Laforin, a Dual Specificity Phosphatase Involved in Lafora Disease, Is Present Mainly as Monomeric Form with Full Phosphatase Activity
por: Dukhande, Vikas V., et al.
Publicado: (2011)

Extraneurological sparing in long‐lived typical Lafora disease
por: Goldsmith, Danielle, et al.
Publicado: (2018)

Genotypes and phenotypes of patients with Lafora disease living in Germany
por: Brenner, David, et al.
Publicado: (2019)

Canine Lafora Disease: An Unstable Repeat Expansion Disorder
por: von Klopmann, Thilo, et al.
Publicado: (2021)

Electro-clinical features and management of the late stage of Lafora disease
por: d'Orsi, Giuseppe, et al.
Publicado: (2022)

A Case of Lafora Disease Diagnosed by Axillary Skin Biopsy
por: Kımıloğlu, Elife, et al.
Publicado: (2021)

Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease
por: Ortolano, Saida, et al.
Publicado: (2014)

Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel
por: Dirani, Maya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a0n9hokhqu8o4qe18mpu41k3a7